Novo Nordisk Annual Report 2021
Contents Introducing Novo Nordisk
Strategic Aspirations
Key risks
Management
Consolidated statements
Additional information.
☑
Commercial execution
Maintaining
commercial
excellence
The COVID-19 pandemic provided the backdrop to
Novo Nordisk's commercial operations in 2021. The
increased risk of serious illness from coronavirus
among people living with diabetes and obesity and
other serious chronic diseases - and the growing
incidence of these conditions around the world -
has made delivering our products to patients more
imperative than ever.
We are increasingly providing a holistic solution to the
challenges of inter-linked cardiometabolic diseases - such
as diabetes, obesity and other serious chronic diseases - by
offering products to patients, healthcare professionals and
payers. In this way we are driving change and adding value for
society, while at the same time building a sustainable business
for the future.
Despite the economic and social disruptions caused by the
pandemic, we successfully launched important new products
and grew market share in 2021, allowing us to make progress
across our strategic aspirations. This robust performance was
underpinned by strong demand for our diabetes treatments
and our new obesity medication, WegovyⓇ.
We are working towards achieving a global diabetes market
value share of one third by 2025. We are also committed to
consolidating and expanding our leading position in obesity
treatment, while our Biopharm division is building a diversified
platform for sustainable growth.
Novo Nordisk Annual Report 2021
30.1%
Value market share for diabetes
8,400
DKK million sales in obesity treatment
30View entire presentation